Drug Profile
NAV 1800
Alternative Names: NAV-1800; RIGScan CR; RIGScan-CR49Latest Information Update: 03 Feb 2016
Price :
$50
*
At a glance
- Originator Neoprobe
- Developer Navidea Biopharmaceuticals
- Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 03 Feb 2016 No recent reports on development identified - Phase-III for Colorectal cancer (Diagnosis, Metastatic disease) in USA (IV)
- 26 Sep 2013 Phase-III clinical trials in Colorectal (diagnosis, metastatic disease) cancer in USA (IV)
- 26 Sep 2013 Phase-III clinical trials in Diagnostic imaging in USA (unspecified route)